New South Wales, Australia: Terminal cancer patients with refractory pain respond favorably to a proprietary cannabis spray containing equal ratios of plant-derived THC and CBD, according to data published in the journal PLOS One.
A team of Australian investigators assessed the safety and efficacy of a novel water-soluble oro-buccal nanoparticle spray containing 2.5 mgs of THC and 2.5 mgs of CBD in a cohort of patients with advanced cancer and intractable pain.
Researchers reported that cannabis dosing was associated with improvements in pain relief among all patients, with those patients suffering from bone metastasis experiencing the greatest levels of relief. No serious adverse events were reported, though some patients did experience drowsiness following treatment.
Patients also reported improvements in appetite and emotional well-being.
“This study demonstrated that the administration of the investigative cannabis-based medicine was generally safe and tolerated in a short-term exposure in a cohort of patients with advanced incurable cancers with controlled pain or intractable pain despite opioid treatment,” authors concluded. “There was a reduction in pain overall for the study cohort of 12 percent by the end of the treatment phase. … [This] cannabis-based medicine … is of significant clinical interest given that this formulation was a self-titrated medicine, that showed preliminary analgesic efficacy in a subgroup of patients.”